Lipocine Inc. (LPCN) Announces First Patient Dosed In Phase 2a Study Of LPCN 1111, A Novel Testosterone Ester For Oral Testosterone Replacement Therapy
5/28/2014 9:22:33 AM
SALT LAKE CITY, May 27, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in a Phase 2a clinical study of LPCN 1111, a novel ester prodrug of testosterone, in hypogonadal males. The primary objectives of the study will be to determine safety, tolerability, single and steady state pharmacokinetics of testosterone following oral administration of LPCN 1111.
Help employers find you! Check out all the jobs and post your resume.
comments powered by